Voice your opinion on congressional bill HR5547-118 and let lawmakers know your stance with UnPac!

Main Subject: Health

Maintaining Investments in New Innovation Act

This bill requires drug products with genetically targeted technology to have had market approval for at least 11 years in order to qualify for the Medicare Drug Price Negotiation Program. (The program requires the Centers for Medicare & Medicaid Services to negotiate the prices of certain prescription drugs under Medicare beginning in 2026. Among other requirements, drugs must have had market approval for at least 7 years (for drug products) or 11 years (for biologics) to qualify for negotiation.)

House committee actions Actions

Committee
Sep. 22 2023	Referred to the Subcommittee on Health.

House floor actions Actions

IntroReferral

Sep. 18
2023

Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Library of Congress Actions

IntroReferral
Sep. 18 2023	Introduced in House Introduced in House

House bill HR5547-118

Maintaining Investments in New Innovation Act

Promote the cause!

Or use this QR code